Meningococcal disease. Meningococcal conjugate polysaccharide vaccines and new generation vaccines. Report 3

Despite the progress in fighting against infectious diseases of bacterial origin, the incidence of generalized forms of meningococcal infection (GFMI) remains a topical public health problem not only in countries with historical high incidence, but also in countries considered to be relatively «secured» in regard to the mentioned infection. In the 60s of the last century the production of high-polymer forms of meningococcal polysaccharides was started. These high molecular weight polysaccharides were used for the development of vaccines. They helped to significantly reduce the incidence of GFMI in certain countries, including the countries of the so-called African «meningitis belt». Unfortunately, polysaccharide vaccines have well-known deficiencies, prompting the researchers to develop advanced conjugate vaccines. Current new generation of vaccines are based on conjugates of polysaccharides of different serogroups with carrier proteins such as tetanus toxoid, a modified diphtheria toxin (CRM₁₉₇) or outer membrane proteins. Mono- and multivalent conjugate vaccines were developed and tested. Conjugate vaccines have several advantages compared to the polysaccharide vaccines. They stimulate the formation of immunological memory, and therefore are able to provide consistent protection against meningococcal disease in children of an early age group. In particular, monovalent conjugate vaccine against serogroup C meningococcal disease were proven to be very effective. This vaccine was successfully used in the UK. There are also tetravalent conjugate vaccines Menactra and Menveo. These preparations consist of serotype A, C, W₁₃₅ and Y meningococcal polysaccharide conjugates. These polysaccharides stimulated the production of bactericidal antibodies in 90% of immunized individuals. Certain success was also achieved in developing genetically engineered vaccines and the vaccines based in meningococcal outer membrane vesicles (OMV-vaccines). OMV-vaccines showed to be effective in the fight against epidemics of meningitis caused by serogroup B meningococcus. Polysaccharide vaccines against serogroup B meningococcus in different designs proved to be ineffective because of their low immunogenicity. There are certain difficulties in developing an ultimate vaccine that protects against GFMI, due to the fact that there is a variety of antigenic types of serogroup B meningococcus. So far the scientists only have managed to develop a strain-specific vaccine suitable for fighting GFMI outbreaks, caused by the specific strain of serogroup B meningococcus. The opportunities to enhance the efficacy of vaccines against serogroup B meningococcus are still being discussed.

штаммо-специфические менингококковые вакцины, генерализованные формы менингококковой инфекции, конъюгаты менингококковых полисахаридов, антигенные варианты менингококка, meningococcal disease, generalized forms of meningococcal infection, conjugate vaccines, polysaccharide vaccines, strain-specific protective effect

1. Grechuha TA, Galitskaya MG. Particularly dangerous infections: meningococcal infection and ways of its prevention. Praktika pediatra 2012; (6): 5–9 (in Russian).

2. Abramtseva MV, Tarasov AP, Nemirovskaya TI. Meningococcal disease. Polysaccharide meningococcal vaccines. The historical aspects and the current state of vaccine development. Report 2. Biopreparaty 2015; (3): 25–32 (in Russian).

3. World Health Organization. Meningococcal vaccines: WHO position paper. Weekly epidemiological record. 2011; 86: 521–40.

4. Fedoseenko MV, Galitskaya MG, Namazova LS. The era of conjugate vaccines: the international experience of successful application. Pediatricheskaya farmakologiya 2008; 5(6): 8–14 (in Russian).

5. Platonov AE, Harit SM, Platonova OV. Vaccine meningococcal disease in the world and in Russia. Epidemiologiya i vaktsinoprofilaktika 2009; 5: 32–46 (in Russian).

6. Pichichero ME. Protein carriers of conjugate vaccines Characteristics, development, and clinical trials. Hum Vaccin Immunother. 2013; 9(12): 2505–23.

7. World Health Organization. Mediacenter. Meningococcal Meningitis. Fact Sheet ¹ 141 updated February 2015. Available from: http://www.who.int/mediacenter/factsheets/fs141/en.

8. Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Plotkin SA, Orenstein WA. Vaccines. 6th edition. Saunders: Elsevier; 2013. P. 389–418.

9. Snape MD, Kelly DF, Lewis S. Seroprotection against serogroup Ñ meningococcal disease in adolescents in the United Kingdom: observational study. Brit Med J. 2008; 336: 1487–91.

10. Borrow R, Goldblatt D, Finn A. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun. 2003; 71: 554–5.

11. Gray SG, Trotter CT, Ramsay ME, Guiver M, Fox AJ, Borrow R, Mallard RH, Kaczmarski EB. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol. 2006; 55: 887–96.

12. Borrow R, Goldblatt D, Andrews N, Southern J, Ashton L, Deane S. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis. 2002; 186: 1353–7.

13. Rennels M, King J Jr, Ryall R. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J. 2004; 23: 429–35.

14. Pichichero M, Casey J, Blatter M. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J. 2005; 24: 57–62.

15. Snape MD, Perrett KP, Ford KJ. Immunogenecity of a tetravalent meningococcal vaccine in infants: a randomized trial. J Amer Med Ass. 2008; 299(2): 173–84.

16. Maiden MC, Ibarz-Pavon AB, Urwin R. Impact of meningococcal serogroup C conjugate vaccines on carriage and heard immunity. J Infect Dis. 2008; 197(5): 737–43.

17. Campbell H, Andrews N, Borrow R. Updated post-licensure surveillance of meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlate of protection and modeling predictions of the duration of heard immunity. Clin Vaccine Immunol. 2010; 17: 840–7.

18. Gatchalian S, Palestroque E, de Vleeschauwer I. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis — hepatitis  — Haemophilus influenzae type B — Neisseria meningitidis serogroups A and Ñ vaccine: a randomized dose-ranging trial of the conjugate vaccine components. Int J Infect Dis. 2008; 12: 278–88.

19. CDC. Miningococcal Home Surveillance Systems National Notifiable Desease Surveillance Systems and Active Bacterial Core surveillance. Available from http://www.cdc.gov/meningococcalsurveillance/.

20. Wyle FA, Artenstein MS, Brand BL, Tramont EC. Immunological response of man to group B meningococcal polysaccharide vaccines. J Infect Dis. 1972; 126: 514–22.

21. Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun. 1983; 40: 257–64.

22. Hayrinngen J, Jenninngs HJ, Raff HV, Rougon G. Antibodies to polysialic acid and its N-propyl derivate: binding properties and interaction with human embryonal brain glycopeptides. J Infect Dis. 1995; 171: 1481–90.

23. Poolman JT. Development of a meningococcal vaccine. Infect Agents Dis. 1995; 4: 13–28.

24. Zollinger WD, Moran E. Meningococcal vaccines — present and future. Trans Roy Soc Trop Med Hyg. 1991; 85(Suppl. 1): 37–43.

25. Frasch CE. Vaccines for prevention of meningococcal disease. Clin Microbiol Rev. 1989; 2 (Suppl): 134–8.

26. Delvig AA, Semenov BF, Rosenquist E, Robinson DG. Neisseria meningitidis: from the antigenic structure to the next generation of vaccines. Moscow: Meditsina; 2000 (in Russian).

27. Zollinger WD, Kasper DL, Veltri BJ, Artenstein MS. Isolation and characterization of a native cell wall complex from Neisseria meningitidis. Infect Immun. 1972; (6): 835–51.

28. Zollinger WD, Mandrell RE, Altieri P, Berman S. Safety and immunogenecity of a Nesseria meningitidis type 2 protein vaccines in animals and humans. J Infect Dis. 1978; 137: 728–39.

29. Frasch CE, Peppier MS. Protection against group  Neisseria meningitidis disease: Preparation of soluble protein and protein-polysaccharide immunogens. Infect Immun. 1982; 37: 271–80.

30. Frasch CE, Coetzee GJ, Zahradnik JM, Feldman HA. Development and evaluation of group  serotype 2 protein vaccines: report of a group  field trial. Med Trop. 1983; 43: 177–83.

31. Froholm LO, Berdal BP, Bovre K, Gaustad P. Meningococcal group  vaccine trial in Norway Preliminary report of results available November 1983. NIPH Ann. 1983; (6): 133–8.

32. Rosenqvist E, Tjade Ò, Froholm LO, Frasch CE. An ELISA study of the antibody response after vaccination with a combined meningococcal group  polycaccharide and serotype 2 outer membrane protein vaccine. NIPH Ann. 1983; (6): 139–49.

33. Wedege E, Froholm LO. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect Immun. 1986; 51: 571–8.

34. Rosenqvist E, Harthug S, Froholm LO, Hoiby EA. Antibody responses to serogroup  meningococcal outer membrane antigens after vaccination and infection. J Clin Microbiol. 1988; 26: 1543–8.

35. Poolman JT. Clinical trials with outer membrane protein vaccines and PorA recombinant vaccines. In: Zollinger WD, Frash CE, Deal CD, eds. Proceedings of the 10 International Pathogenic Neisseria Coonference. 1996. P. 117–22.

36. Highlits of Prescribing Information Trumenba (meningococcal group B Vaccine). 2014. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf.

37. Highlits of Prescribing Information Bexsero (meningococcal group B Vaccine). 2015. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM431447.pdf.

38. Panatto D, Amicizia D, Lai PL, Cristina ML, Domnich A, Gaspsrini R. New versus old meningococcal Group B vaccines: How the new ones may benefit infants & toddlers. Indian J Med Res. 2013; 138(6): 835–46.

39. Hosking J, Rasanathan K, Mow FC. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup  meningococcal vaccine given to preteens. Clin Vaccine Immunol. 2007; 14: 1393–9.

40. Galloway Y, Stehr-Green P, McNicholas A, O’Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group  meningococcal vaccine in children aged under 5 years. Int J Epidemiol. 2009; 38: 413–8

41. Annual WHO / UNICEF Join Reporting Form updated 2014. Available from: http://www.who.int/immunization/monitoring_surveillance/ data/schedule_data.